White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network

Seonjoo Lee(New York Psychoanalytic Society and Institute), Fawad Viqar(Fordham University), Molly E. Zimmerman(Albert Einstein College of Medicine), Atul Narkhede(Columbia University), Giuseppe Tosto(NewYork–Presbyterian Hospital), Tammie L.S. Benzinger(Washington University in St. Louis), Daniel S. Marcus(Washington University in St. Louis), Anne M. Fagan(Washington University in St. Louis), Alison Goate(Icahn School of Medicine at Mount Sinai), Nick C. Fox(UK Dementia Research Institute), Nigel J. Cairns(Washington University in St. Louis), David M. Holtzman(Washington University in St. Louis), Virginia Buckles(Washington University in St. Louis), Bernardino Ghetti(Indiana University School of Medicine), Eric McDade(Washington University in St. Louis), Ralph N. Martins(Edith Cowan University), Andrew J. Saykin(Indiana University School of Medicine), Colin L. Masters(The University of Melbourne), John M. Ringman(University of Southern California), Natalie S. Ryan(UK Dementia Research Institute), Stefan Förster(German Center for Neurodegenerative Diseases), Christoph Laske(German Center for Neurodegenerative Diseases), Peter R. Schofield(UNSW Sydney), Reisa A. Sperling(Brigham and Women's Hospital), Stephen Salloway(Brown University), Stephen Correia(Brown University), Clifford R. Jack(Mayo Clinic in Arizona), Michael W. Weiner(San Francisco VA Medical Center), Randall J. Bateman(Washington University in St. Louis), John C. Morris(Washington University in St. Louis), Richard Mayeux(NewYork–Presbyterian Hospital), Adam M. Brickman(NewYork–Presbyterian Hospital), for the Dominantly Inherited Alzheimer Network
Annals of Neurology
March 26, 2016
Cited by 546Open Access
Full Text

Abstract

OBJECTIVE: White matter hyperintensities (WMHs) are areas of increased signal on T2-weighted magnetic resonance imaging (MRI) scans that most commonly reflect small vessel cerebrovascular disease. Increased WMH volume is associated with risk and progression of Alzheimer's disease (AD). These observations are typically interpreted as evidence that vascular abnormalities play an additive, independent role contributing to symptom presentation, but not core features of AD. We examined the severity and distribution of WMH in presymptomatic PSEN1, PSEN2, and APP mutation carriers to determine the extent to which WMH manifest in individuals genetically determined to develop AD. METHODS: The study comprised participants (n = 299; age = 39.03 ± 10.13) from the Dominantly Inherited Alzheimer Network, including 184 (61.5%) with a mutation that results in AD and 115 (38.5%) first-degree relatives who were noncarrier controls. We calculated the estimated years from expected symptom onset (EYO) by subtracting the affected parent's symptom onset age from the participant's age. Baseline MRI data were analyzed for total and regional WMH. Mixed-effects piece-wise linear regression was used to examine WMH differences between carriers and noncarriers with respect to EYO. RESULTS: Mutation carriers had greater total WMH volumes, which appeared to increase approximately 6 years before expected symptom onset. Effects were most prominent for the parietal and occipital lobe, which showed divergent effects as early as 22 years before estimated onset. INTERPRETATION: Autosomal-dominant AD is associated with increased WMH well before expected symptom onset. The findings suggest the possibility that WMHs are a core feature of AD, a potential therapeutic target, and a factor that should be integrated into pathogenic models of the disease. Ann Neurol 2016;79:929-939.


Related Papers

No related papers found

Powered by citation graph analysis